Date & Time of Session - 9/22/25 - from 12:00 - 1:00 PM

Need/Overview
Direct oral anticoagulants (DOACs) have revolutionized anticoagulation therapy by offering simplified dosing and fewer monitoring requirements compared to traditional agents like warfarin. However, their use in special populations—such as, but not limited to, patients with obesity, renal or hepatic impairment, or those post-bariatric/gastric surgery—presents unique clinical challenges. These groups are often underrepresented in pivotal trials, leaving gaps in evidence-based guidance. Staying current on emerging data and guideline updates is essential to ensure safe and effective anticoagulation management. This presentation will provide a focused review of recent literature, clinical pearls, and practical strategies for optimizing DOAC therapy in complex populations. By enhancing understanding of pharmacokinetic considerations, dosing adjustments, and risk mitigation, practitioners will be better equipped to make informed decisions and improve patient outcomes in real-world settings.

Objectives
Upon completion of this activity, participants will be able to:
1. Identify special populations where DOAC use requires caution or modification.
2. Review recent clinical data and guideline updates related to DOACs.
3. Apply evidence-based recommendations to optimize DOAC therapy in complex patient scenarios.

Target Audience
Free 1 credit hour of Continuing Education for St Elizabeth Health Care providers, Pharmacists, Residents and Students

Special Services
If you require special assistance to attend this event, please call Deanna Fliehman at (859) 301-6191

Speaker
Dan Giller, PharmD
PGY2 Ambulatory Care Pharmacy Resident
St Elizabeth Healthcare - Edgewood, Kentucky